# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Lorraine Hansberry (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML034-SYN
- Date: 2026-08-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Odette Marchetti-Fields, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Review after six cycles: restaging results and the decision for surgery. **S**

## History of present illness

Ms. Hansberry returns two weeks after her sixth and last cycle before surgery. The diarrhea after cycle 5 settled within two days with loperamide, fluids and potassium, and with irinotecan reduced for cycle 6 she had only two loose stools. The restaging CT four days ago shows the tumor smaller and less contact with the vein, with no spread, and the tumor board recommends surgery; she met the surgeon and has chosen to go ahead. The interim CT ordered before cycle 5 was never scheduled. The cold-induced tingling is fading and her fingertips feel almost normal. Pain is 1 out of 10 and she takes oxycodone once every few days. She walks 30 minutes a day to prepare for surgery. Home fasting glucose is 115 to 135 mg/dL. She has had no bleeding on apixaban. She has written most mornings this month. She has had no thoughts of self-harm. **S**

| Element | Detail |
|---|---|
| Treatment | Six cycles of modified FOLFIRINOX; irinotecan reduced for cycle 6 after grade 2 diarrhea |
| Restaging CT | Mass 2.1 cm from 3.1 cm; vein contact about 150 degrees; no arterial contact; no metastases |
| Decision | Pancreaticoduodenectomy with vein resection in two weeks |
| Effects | Diarrhea resolved; neuropathy fading |
| Preparation | Walking 30 minutes daily; protein supplements |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Energy improving; weight 54.2 kg; no fever |
| Gastrointestinal | Negative | Diarrhea resolved; stools formed; no nausea; no black stools |
| Neurological | Positive | Fingertip tingling fading; no weakness |
| Hematologic and lymphatic | Negative | No bleeding or bruising on apixaban |
| Respiratory | Negative | No cough or breathlessness |
| Psychiatric | Positive | Hopeful and nervous about surgery; PHQ-9 6; no thoughts of self-harm |

6 systems reviewed. **S**

## Current medications

- Pantoprazole 40 mg delayed-release oral tablet, one tablet by mouth once daily before breakfast **S**
- Oxycodone 5 mg oral tablet, one tablet by mouth every 4 hours as needed for pain **S**
- Senna 8.6 mg oral tablet, two tablets by mouth at night while taking oxycodone **S**
- Pancrelipase delayed-release capsule (lipase 36,000 units), two capsules with each meal and one with each snack **S**
- Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nausea **S**
- Olanzapine 5 mg oral tablet, one tablet by mouth at night on days 1 to 4 of each cycle **S**
- Loperamide 2 mg oral capsule, two capsules at the first loose stool, then one after each loose stool, no more than eight a day unless directed **S**
- Apixaban 2.5 mg oral tablet, one tablet by mouth twice daily during chemotherapy, stopped three days before surgery **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/72 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 54.2 kg; BMI 20.4 kg/m². All vital signs are synthetic.

Hemoglobin: 10.9 g/dL (low); White cell count: 7.8 10*3/uL; Absolute neutrophil count: 4.9 10*3/uL; Platelets: 176 10*3/uL; Sodium: 138 mmol/L; Potassium: 4.1 mmol/L; Creatinine: 0.76 mg/dL; eGFR (CKD-EPI 2021): 107 mL/min/1.73 m²; Glucose: 124 mg/dL (high); ALT: 24 U/L; AST: 26 U/L; Alkaline phosphatase: 98 U/L; Total bilirubin: 0.5 mg/dL; Albumin: 3.6 g/dL; Hemoglobin A1c: 7% (high); CA 19-9: 41 U/mL (high); INR: 1; PHQ-9: 6; Pain score (0 to 10): 1. All results are synthetic.

## Change since baseline

- Hemoglobin: 9.1 g/dL (low) at baseline, 10.9 g/dL (low) at this visit **S**
- White cell count: 7.4 10*3/uL at baseline, 7.8 10*3/uL at this visit **S**
- Platelets: 388 10*3/uL at baseline, 176 10*3/uL at this visit **S**
- Sodium: 138 mmol/L at baseline, 138 mmol/L at this visit **S**
- Potassium: 4 mmol/L at baseline, 4.1 mmol/L at this visit **S**
- Creatinine: 0.7 mg/dL at baseline, 0.76 mg/dL at this visit **S**
- eGFR (CKD-EPI 2021): 118 mL/min/1.73 m² at baseline, 107 mL/min/1.73 m² at this visit **S**
- Glucose: 132 mg/dL (high) at baseline, 124 mg/dL (high) at this visit **S**
- ALT: 48 U/L (high) at baseline, 24 U/L at this visit **S**
- AST: 41 U/L (high) at baseline, 26 U/L at this visit **S**
- Alkaline phosphatase: 236 U/L (high) at baseline, 98 U/L at this visit **S**
- Total bilirubin: 1.6 mg/dL (high) at baseline, 0.5 mg/dL at this visit **S**
- Albumin: 3.6 g/dL at baseline, 3.6 g/dL at this visit **S**
- Hemoglobin A1c: 6.6% (high) at baseline, 7% (high) at this visit **S**
- Pain score (0 to 10): 5 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; weight 54.2 kg; blood pressure 112/72, pulse 80 |
| Eyes | No icterus |
| Abdomen | Soft, non-tender; no mass; port site clean |
| Neurological | Light touch at the fingertips almost normal; vibration and reflexes normal |
| Extremities | No leg swelling |
| Psychiatric | Calm, focused, asks about recovery time for writing |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pancreatic head adenocarcinoma, borderline resectable, after six cycles of modified FOLFIRINOX** (C25.0). A partial response on CT and CA 19-9 41 U/mL from 486, with no progression, so resection is recommended by the tumor board. Fit for surgery: albumin 3.6 g/dL, weight 2 percent below the weight at diagnosis, normal kidney and liver function, INR 1.0. **S**
   - Pylorus-preserving pancreaticoduodenectomy with superior mesenteric vein resection in two weeks.
   - Stop apixaban three days before surgery; enoxaparin for four weeks after it.
   - Continue walking and protein supplements until surgery.
2. **Chemotherapy-induced diarrhea** (K52.1). Resolved after the cycle 5 episode; only two loose stools after cycle 6 at the reduced irinotecan dose. **S**
   - Problem resolved.
3. **Diabetes due to the pancreatic cancer** (E08.9). A1c 7.0% and glucose 124 mg/dL on no treatment. Resection of the head of the pancreas often worsens diabetes; insulin may be needed after surgery. **S**
   - Glucose monitoring in hospital, with basal insulin if needed.
4. **Oxaliplatin neuropathy, grade 1** (G62.0). Fading two weeks after the last oxaliplatin dose. **S**
   - Review after surgery.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Restaging CT after chemotherapy before surgery | After completing therapy before surgery | Up to date | Four days ago: partial response; vein contact about 150 degrees; no arterial contact; no metastases |
| Imaging | Interim restaging CT | Every two months during chemotherapy before surgery | Deferred | A deviation: the interim CT ordered at cycle 4 was never scheduled. No harm resulted: CA 19-9 kept falling and today's CT shows a response without progression. Corrective action: the nurse navigator now tracks every imaging order to a booked date |
| Laboratory | CA 19-9 | At diagnosis after biliary drainage, every two cycles during treatment, before surgery, after surgery, then every three to six months | Completed today | 41 U/mL, from 210 at cycle 4 and 486 at diagnosis |
| Laboratory | Blood count with neutrophils and platelets | Before surgery | Completed today | Hemoglobin 10.9 g/dL, white cells 7.8, neutrophils 4.9, platelets 176 |
| Laboratory | Kidney and liver function, electrolytes and albumin before surgery | Within 30 days before surgery | Completed today | Sodium 138, potassium 4.1 mmol/L; creatinine 0.76 mg/dL, eGFR 107; ALT 24, AST 26, alkaline phosphatase 98 U/L, bilirubin 0.5 mg/dL; albumin 3.6 g/dL |
| Laboratory | INR before surgery | Before surgery | Completed today | 1.0 |
| Referral | Pancreatic tumor board and surgical oncology | After restaging | Up to date | Tumor board three days ago and surgical consultation: resection recommended and accepted |
| Medication safety | Anticoagulation around surgery | Before and after surgery | Completed today | Apixaban stopped three days before surgery; enoxaparin 40 mg daily for four weeks after it |
| Examination | Oxaliplatin neuropathy: symptoms and examination | At each visit after oxaliplatin | Completed today | Grade 1 and fading |
| Survey | Pain score and opioid review | Each visit | Completed today | Pain 1 out of 10; oxycodone once every few days |
| Self-management | Weight, nutrition and enzyme replacement | Each visit | Completed today | Weight 54.2 kg, 2 percent below the weight at diagnosis; protein supplements and walking to prepare for surgery |
| Laboratory | Glucose and home readings | Each visit and before each cycle | Completed today | Glucose 124 mg/dL |
| Laboratory | A1c | Every three months while treatment changes | Completed today | 7.0%, from 6.6% at the first visit |
| Examination | Dilated eye examination and urine albumin-to-creatinine ratio | At diagnosis of diabetes, then yearly | Deferred | Still outstanding (see the deviation at cycle 4); booked with the visit after surgery |
| Survey | Distress and depression screen (PHQ-9, GAD-7) | At diagnosis, at each treatment phase, and when symptoms change | Completed today | PHQ-9 6 |

## Goal progress

- Endoscopy and pancreas-protocol CT within one week, tissue diagnosis and biliary drainage within two weeks, and a tumor board plan within three weeks of presentation. Outcome by 2026-05-04: Endoscopy in two days, CT in three, EUS biopsy and stent in one week, tumor board in nine days, consultation at two weeks. **S**
- Germline genetic testing with counseling and tumor molecular profiling resulted before surgery. Outcome by 2026-06-29: Germline panel negative; tumor KRAS G12D, microsatellite stable, no targetable alteration. **S**
- Six cycles of modified FOLFIRINOX before surgery with no delay of more than one week. Outcome by 2026-08-10: Six cycles; one dose reduction of irinotecan after diarrhea; CT shows a partial response. **S**
- Resection with clear margins if restaging shows no progression. In progress; target 2026-10-05. **S**
- Pain 3 out of 10 or less with a clear head for writing. Outcome by 2026-06-29: Pain 1 to 2 out of 10 on oxycodone 5 mg once or twice a day. **S**
- Weight kept within 5 percent of the weight at diagnosis through chemotherapy, with enzyme replacement and dietitian support. Outcome by 2026-08-10: Weight 54.2 kg before surgery, 2 percent below the weight at diagnosis. **S**
- PHQ-9 below 10 throughout treatment, with support she chooses and palliative care alongside cancer treatment. In progress; target 2026-10-05. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Pancreatic Adenocarcinoma (2026), National Comprehensive Cancer Network
- Khorana AA, et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016;34(21):2541-2556 (PMID 27247221) (2016), American Society of Clinical Oncology
- Key NS, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update. J Clin Oncol 2023;41(16):3063-3071 (PMID 37075273) (2023), American Society of Clinical Oncology
- Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (PMID 32663120) (2020), American Society of Clinical Oncology
- American Diabetes Association Professional Practice Committee. Standards of Care in Diabetes-2026 (classification of diabetes, including diabetes of the exocrine pancreas) (2026), American Diabetes Association
- CMID: Clinical Monitoring Intelligence Database, diabetes mellitus (type 2) and anemia monographs (2026), Aether Forge
- Depression and Suicide Risk in Adults: Screening (2023), U.S. Preventive Services Task Force

## Follow-up

- Surgery in two weeks. Primary care review about six weeks after surgery with the pathology. Call for fever, bleeding, or leg swelling before then. **S**
- Next scheduled visit 2026-10-05: six weeks after pancreaticoduodenectomy: pathology, diabetes and enzyme replacement after surgery, and the plan for chemotherapy after surgery. **S**
